Immunology/Inflammation

Immunology/Inflammation(免疫及炎症)

The immune and inflammation-related pathway including the Toll-like receptors pathway, the B cell receptor signaling pathway, the T cell receptor signaling pathway, etc.

Toll-like receptors (TLRs) play a central role in host cell recognition and responses to microbial pathogens. TLR4 initially recruits TIRAP and MyD88. MyD88 then recruits IRAKs, TRAF6, and the TAK1 complex, leading to early-stage activation of NF-κB and MAP kinases [1]. TLR4 is endocytosed and delivered to intracellular vesicles and forms a complex with TRAM and TRIF, which then recruits TRAF3 and the protein kinases TBK1 and IKKi. TBK1 and IKKi catalyze the phosphorylation of IRF3, leading to the expression of type I IFN [2].

BCR signaling is initiated through ligation of mIg under conditions that induce phosphorylation of the ITAMs in CD79, leading to the activation of Syk. Once Syk is activated, the BCR signal is transmitted via a series of proteins associated with the adaptor protein B-cell linker (Blnk, SLP-65). Blnk binds CD79a via non-ITAM tyrosines and is phosphorylated by Syk. Phospho-Blnk acts as a scaffold for the assembly of the other components, including Bruton’s tyrosine kinase (Btk), Vav 1, and phospholipase C-gamma 2 (PLCγ2) [3]. Following the assembly of the BCR-signalosome, GRB2 binds and activates the Ras-guanine exchange factor SOS, which in turn activates the small GTPase RAS. The original RAS signal is transmitted and amplified through the mitogen-activated protein kinase (MAPK) pathway, which including the serine/threonine-specific protein kinase RAF followed by MEK and extracellular signal related kinases ERK 1 and 2 [4]. After stimulation of BCR, CD19 is phosphorylated by Lyn. Phosphorylated CD19 activates PI3K by binding to the p85 subunit of PI3K and produce phosphatidylinositol-3,4,5-trisphosphate (PIP3) from PIP2, and PIP3 transmits signals downstream [5].

Central process of T cells responding to specific antigens is the binding of the T-cell receptor (TCR) to specific peptides bound to the major histocompatibility complex which expressed on antigen-presenting cells (APCs). Once TCR connected with its ligand, the ζ-chain–associated protein kinase 70 molecules (Zap-70) are recruited to the TCR-CD3 site and activated, resulting in an initiation of several signaling cascades. Once stimulation, Zap-70 forms complexes with several molecules including SLP-76; and a sequential protein kinase cascade is initiated, consisting of MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAPKK), and MAP kinase (MAPK) [6]. Two MAPK kinases, MKK4 and MKK7, have been reported to be the primary activators of JNK. MKK3, MKK4, and MKK6 are activators of P38 MAP kinase [7]. MAP kinase pathways are major pathways induced by TCR stimulation, and they play a key role in T-cell responses.

Phosphoinositide 3-kinase (PI3K) binds to the cytosolic domain of CD28, leading to conversion of PIP2 to PIP3, activation of PKB (Akt) and phosphoinositide-dependent kinase 1 (PDK1), and subsequent signaling transduction [8].

 

References

[1] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nature immunology, 2010, 11(5): 373-384.

[2] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34(5): 637-650.

[3] Packard T A, Cambier J C. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation[J]. F1000Prime Rep, 2013, 5(40.10): 12703.

[4] Zhong Y, Byrd J C, Dubovsky J A. The B-cell receptor pathway: a critical component of healthy and malignant immune biology[C]//Seminars in hematology. WB Saunders, 2014, 51(3): 206-218.

[5] Baba Y, Matsumoto M, Kurosaki T. Calcium signaling in B cells: regulation of cytosolic Ca 2+ increase and its sensor molecules, STIM1 and STIM2[J]. Molecular immunology, 2014, 62(2): 339-343.

[6] Adachi K, Davis M M. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells[J]. Proceedings of the National Academy of Sciences, 2011, 108(4): 1549-1554.

[7] Rincón M, Flavell R A, Davis R A. The Jnk and P38 MAP kinase signaling pathways in T cell–mediated immune responses[J]. Free Radical Biology and Medicine, 2000, 28(9): 1328-1337.

[8] Bashour K T, Gondarenko A, Chen H, et al. CD28 and CD3 have complementary roles in T-cell traction forces[J]. Proceedings of the National Academy of Sciences, 2014, 111(6): 2241-2246.

研究方向

Immunology/Inflammation 相关产品(4245)

  • GC62586 structure
    GC62586IACS-8803 disodium
    CAS: 2243079-36-7
    纯度: >99.00%

    IACS-8803 disodium 是一种高效环状二核苷酸的 STING 激动剂,具有强大的全身抗肿瘤作用。

  • GC62590 structure
    GC62590E64FC26
    CAS: 2285446-62-8
    纯度: >99.00%

    E64FC26 是蛋白质二硫键异构酶 (PDI) 家族的一种有效的泛抑制剂,对 PDIA1、PDIA3、PDIA4、TXNDC5 和 PDIA6 的 IC50 分别为 1.9、20.9、25.9、16.3 和 25.4 μM。E64FC26 显示抗骨髓瘤活性。

  • GC62594 structure
    GC62594hnRNPK-IN-1
    CAS: 2313528-04-8
    纯度: >97.00%

    hnRNPK-IN-1 是一种异质核糖核蛋白 K (hnRNPK) 结合配体,用 SPR 和 MST 测量的 Kd 值分别为 4.6 μM 和 2.6 μM。hnRNPK-IN-1 通过破坏 hnRNPK 和 c-myc 启动子的结合来抑制 c-myc 转录。hnRNPK-IN-1诱导 Hela 细胞凋亡 (apoptosis),并具有很强的抗肿瘤活性。

  • GC62596 structure
    GC62596CDK7-IN-3
    CAS: 2417302-07-7
    纯度: >99.50%

    CDK7-IN-3 (CDK7-IN-3) 是一种具有口服活性的高选择性非共价 CDK7 抑制剂,KD 为 0.065 nM。 CDK7-IN-3 对 CDK2 (Ki=2600 nM)、CDK9 (Ki=960 nM)、CDK12 (Ki=870 nM) 显示出较差的抑制作用。 CDK7-IN-3 诱导肿瘤细胞凋亡并具有抗肿瘤活性。

  • GC62598 structure
    GC62598MI-1061 TFA
    CAS: 1410737-35-7

    MI-1061 TFA 是一种有效的,口服可生物利用的,化学稳定性的 MDM2 (MDM2-p53 互作) 抑制剂 (IC50=4.4 nM; Ki=0.16 nM)。MI-1061 TFA 激活小鼠 SJSA-1 异种移植瘤组织中 p53 并诱导凋亡,具有抗肿瘤活性。

  • GC62608 structure
    GC62608E7766 diammonium salt
    CAS: 2242635-03-4

    E7766 diammonium salt, a macrocycle-bridged STING agonist with a Kd of 40 nM, shows potent pan-genotypic and antitumor activities.

  • GC62609 structure
    GC62609E7766 disodium
    CAS: 2242636-28-6

    E7766 disodium 是一种大环桥连 STING 激动剂,Kd 为 40 nM。E7766 disodium 显示出强大的泛基因型和抗肿瘤活性。

  • GC62615 structure
    GC62615AS-99
    CAS: 2323623-93-2

    AS-99 是一流的、有效的、选择性的 ASH1L 组蛋白甲基转移酶抑制剂(IC50=0.79μ;M,Kd=0.89μ;M),具有抗白血病活性。 AS-99 阻断细胞增殖,诱导细胞凋亡和分化,下调 MLL 融合靶基因,并减少体内白血病负担。

  • GC62620 structure
    GC62620NHWD-870
    CAS: 2115742-03-3
    纯度: >98.00%

    NHWD-870 inhibits CSF1 expression through suppressing BRD4 and its target HIF1α.

  • GC62621 structure
    GC62621Milademetan tosylate hydrate
    CAS: 2095625-97-9
    纯度: >98.00%

    Milademetan (DS-3032) tosylate hydrate 是特异性的、具有口服活性的 MDM2 抑制剂,用于急性髓系白血病和实体肿瘤的研究。Milademetan (DS-3032) tosylate hydrate 可诱导 G1 细胞周期阻滞、衰老和凋亡。

  • GC62626 structure
    GC62626ICCB-19 hydrochloride
    CAS: 1803605-68-6
    纯度: >99.00%

    ICCB-19 hydrochloride is an inhibitor of TNFRSF1A Associated Via Death Domain (TRADD) with IC50 of 1.12 μM and 2.01 μM for protecting Velcade-induced apoptosis in Jurkat cells and protecting RDA in MEFs, respectively. ICCB-19 indirectly inhibits Receptor-interacting serine/threonine-protein kinase 1 (RIPK1). ICCB-19 effectively induces autophagy.

  • GC62630 structure
    GC62630TAS-117 hydrochloride
    纯度: >98.50%

    TAS-117 hydrochloride 是一种有效、选择性、具有口服活性的别构 Akt 抑制剂 (对 Akt1、2 和 3 的 IC50 分别为 4.8、1.6 和 44 nM)。TAS-117 hydrochloride 激发抗骨髓瘤活性并增强蛋白酶体抑制诱导的致命内质网应激。TAS-117 hydrochloride 诱导细胞凋亡 (apoptosis) 和自噬 (autophagy)。

  • GC62633 structure
    GC62633GGTI-2154
    CAS: 251577-10-3

    GGTI-2154 是一种有效和选择性的 geranylgeranyltransferase I (GGTase I) 抑制剂,IC50 值为 21 nM。GGTI-2154 对 GGTase I 的选择性是 FTase (IC50=5600 nM) 的 200 倍以上。GGTI-2154 可用于癌症的研究。

  • GC62636 structure
    GC62636Resiquimod-d5
    CAS: 2252319-44-9
    纯度: >98.00%

    Resiquimod-d5 (R848-d5) 是 Resiquimod 的氘代物。Resiquimod 是一种 TLR7/TLR8 的激动剂, 可诱导细胞因子如 TNF-α,IL-6 和 IFN-α 的上调。

  • GC62639 structure
    GC62639rel-Zotatifin
    CAS: 2098191-54-7

    reli -Zotatifin是Zotatifin的外消旋异构体,作为eIF4A抑制剂,活性小于Zotatifin。Zotatifin (eFT226) 是一种有效,选择性和耐受性良好的 eIF4A 抑制剂。Zotatifin 可促进 eIF4A 与 5’-UTRs 中具有识别基序的特定 mRNA 序列结合 (IC50=2 nM),并干扰 eIF4F 起始复合物的组装。

  • GC62640 structure
    GC62640APG-1387
    CAS: 1570231-89-8
    纯度: >99.00%

    APG-1387 是一种二价 SMAC 模拟物,是 IAP 拮抗剂,可阻断 IAP 家族蛋白 (XIAP,cIAP-1,cIAP-2 和 ML-IAP) 的活性。APG-1387 诱导 cIAP-1 和 XIAP 蛋白降解以及 caspase-3 激活和 PARP 裂解,从而导致细胞凋亡。APG-1387 可用于肝细胞癌,卵巢癌和鼻咽癌的研究。

  • GC62641 structure
    GC62641WEHI-9625
    CAS: 2595314-46-6
    纯度: >99.00%

    WEHI-9625 是一种首创的,三环砜小分子凋亡抑制剂,EC50 值为 69 nM。WEHI-9625 与 VDAC2 结合可促进其抑制小鼠 BAK 诱导的细胞凋亡的能力,但对人 BAK 和与凋亡效应密切相关的 BAX 因子均完全无效。

  • GC62652 structure
    GC62652UZH1a
    纯度: >98.50%

    UZH1a 是一种有效和选择性的 METTL3 抑制剂,IC50 值为 280 nM。UZH1a 可用于细胞进程的转录组调控。UZH1a 具有抗肿瘤活性。UZH1a 也可用作研究 METTL3 的化学探针。

  • GC62654 structure
    GC62654GSK778
    CAS: 2451862-42-1
    纯度: >99.00%

    GSK778 (iBET-BD1) is a strong BD1 bromodomain inhibitor of the BET proteins, with IC50 value of 75 nM for BRD2 BD1, 41 nM for BRD3 BD1, 41 nM for BRD4 BD1, and 143 nM for BRDT BD1.

  • GC62657 structure
    GC62657MRIA9
    CAS: 2750707-05-0
    纯度: >98.00%

    MRIA9 是 ATP 竞争性的、pan-SIK 和 PAK2/3 抑制剂,其对 SIK1、SIK2 和 SIK3 的 IC50 值分别为 516 nM, 180 nM 和 127 nM。

  • GC62659 structure
    GC62659IL-17A inhibitor 1
    CAS: 2452464-73-0
    纯度: >99.50%

    IL-17A inhibitor 1 (example 24) 是 IL-17A 的抑制剂,其在alphalisa assay和HT-29 细胞中的 IC50 值分别为 <9.45 nM 和 9.3 nM。

  • GC62664 structure
    GC62664G140
    CAS: 2369751-07-3
    纯度: >98.00%

    G140 is a potent and selective inhibitor of cyclic GMP-AMP synthase (cGAS), with IC50s of 14.0?nM and 442?nM for h-cGAS and m-cGAS, respectively.

  • GC62665 structure
    GC62665JAK2/FLT3-IN-1 TFA
    纯度: >98.50%

    JAK2/FLT3-IN-1 (TFA) 是一种口服有效的双重 JAK2/FLT3 抑制剂,对 JAK2,FLT3,JAK1 和 JAK3 的 IC50 分别为 0.7 nM,4 nM,26 nM 和 39 nM。JAK2/FLT3-IN-1 (TFA) 具有抗癌活性。

  • GC62668 structure
    GC62668TLR7/8-IN-1
    CAS: 2205095-75-4
    纯度: >99.50%

    TLR7/8-IN-1 为 TLR7/TLR8 抑制剂的结晶形式,来自专利 WO2019220390,化合物 2b. TLR7/8-IN-1 可用于自身免疫性疾病的研究。